CIK 0001701108
- Non-accelerated filer
- Smaller reporting company
Spero Therapeutics, Inc.
Sign in to watch- Ticker
- SPRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-242-1600
- Business address
- 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139
- Former names
- Spero Therapeutics, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $42,485
- in 1 filing
Net −$42,485. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-24 | Mahadevia Ankit CEO and President | Exercise or conversion · Stock Option (Right to Buy) | −3,880 | 525,271 | ||
| 2020-06-23 | Mahadevia Ankit CEO and President | Exercise or conversion | +8,045 | $5.90 | $47K | 73,862 |
| 2020-06-23 | Mahadevia Ankit CEO and President | Sale | −8,045 | $14.33 | $115K | 65,817 |
| 2020-06-23 | Mahadevia Ankit CEO and President | Exercise or conversion · Stock Option (Right to Buy) | −8,045 | 529,151 | ||
| 2020-06-23 | Jackson Scott Thomas Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2020-06-22 | Mahadevia Ankit CEO and President | Exercise or conversion | +2,613 | $5.90 | $15K | 68,430 |
| 2020-06-22 | Mahadevia Ankit CEO and President | Sale | −2,613 | $14.30 | $37K | 65,817 |
| 2020-06-22 | Mahadevia Ankit CEO and President | Exercise or conversion · Stock Option (Right to Buy) | −2,613 | 537,196 | ||
| 2020-02-03 | Melnick David A. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2020-02-03 | Mahadevia Ankit CEO and President | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2020-02-03 | Larkin Cristina Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2020-02-03 | Keutzer Timothy Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2020-01-02 | THOMAS FRANK E Director | Grant or award · Stock Option (right to buy) | +2,704 | $6.47 | $17K | 2,704 |
| 2020-01-02 | FORMELA JEAN FRANCOIS Director | Grant or award · Stock Option (right to buy) | +5,408 | $6.47 | $35K | 5,408 |
| 2020-01-02 | VINK PATRICK V.J.J. Director | Grant or award · Stock Option (right to buy) | +5,408 | $6.47 | $35K | 5,408 |
| 2020-01-02 | Deshpande Milind Director | Grant or award · Stock Option (right to buy) | +5,408 | $6.47 | $35K | 5,408 |
| 2019-06-05 | Smith Cynthia Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 | ||
| 2019-06-05 | Pottage John C Jr Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 | ||
| 2019-06-05 | THOMAS FRANK E Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 | ||
| 2019-06-05 | FORMELA JEAN FRANCOIS Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 |
Page 13 of 17 · 340 trades